Could a daily sip of carbon monoxide ease sickle cell pain?
NCT ID NCT06144749
Summary
This early-stage clinical trial is testing the safety and effects of an experimental oral liquid containing carbon monoxide (HBI-002) in people with sickle cell disease. Participants aged 14-55 will take the liquid daily for 14 days. Researchers will monitor side effects, measure drug levels in the blood, and check for changes in pain levels, inflammation, and blood counts.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANEMIA, SICKLE CELL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cevaxin - The Panama Clinic
RECRUITINGPanama City, Panama
-
Hospital Pacífica Salud
RECRUITINGPanama City, Panama
Conditions
Explore the condition pages connected to this study.